Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Administration of Intravenous NRX100 (Ketamine) vs Placebo Infusion for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Patients With Bipolar Depression

NCT03396601 is registered in ClinicalTrials.gov with NeuroRx, Inc. as lead sponsor.

NCT NCT03396601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03396601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Administration of Intravenous NRX100 (Ketamine) vs Placebo Infusion for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Patients With Bipolar Depression
Lead sponsor
NeuroRx, Inc.
Phase
Phase 3
Overall status
Unknown status
Start date
June 25, 2019
Completion date
December 31, 2024
Enrollment
150 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar depression, suicidal ideation